Skip to main content
. Author manuscript; available in PMC: 2017 Sep 2.
Published in final edited form as: J Proteome Res. 2016 Aug 3;15(9):3225–3240. doi: 10.1021/acs.jproteome.6b00430

Figure 2. Multivariate analyses comparing breast cancer (BCa) cell lines in the presence of paclitaxel treatment.

Figure 2

The panels are pairwise supervised analyses (OPLS-DA) of non-treated controls compared to cells treated for 48 hr with paclitaxel [10 nM]. (A.) BT474 (ER+/PR+/HER2+) Luminal A cells. [R2X(cum) = 1, R2Y(cum) = 1, Q2(cum) = 1]. (B.) MCF-7 (ER+/PR+/HER2−) Luminal A cells. [R2X(cum) = 1, R2Y(cum) = 1, Q2(cum) = 1]. (C.) MDA-MB-231 is the TNBC cell line derived from a Caucasian woman. [R2X(cum) = 1, R2Y(cum) = 1, Q2(cum) = 1] (D.) MDA-MB-468 is the TNBC cell line derived from an African-American woman. [R2X(cum) = 1, R2Y(cum) = 1, Q2(cum) = 1].